Eden Radioisotopes and Cross River Infrastructure Partners Sign MOU to Explore Development of a New Generation Medical Radioisotope Reactor in New Brunswick
ALBUQUERQUE, NM AND GREENWICH, CT / ACCESS Newswire / May 6, 2025 / Eden Radioisotopes, LLC ('Eden') and Cross River Infrastructure Partners, LLC ('CRIP') are pleased to announce the execution of a Memorandum of Understanding (MOU) to jointly explore the development of a new nuclear medical radioisotope reactor and hot cell processing facility in the Province of New Brunswick, Canada. This collaboration marks a significant step forward in Canada's efforts to expand its capabilities in nuclear medicine and build a resilient, regionally anchored supply chain for lifesaving radiodiagnostics and radiopharmaceuticals to bolster regional and national healthcare sovereignty by enabling a secure and sustainable supply of critical medical radioisotopes.
Under the terms of the MOU, Eden and CRIP will work together to identify a suitable site in New Brunswick for Eden's proven, proprietary 2 MW, low-enriched uranium (LEU) 'all-target' core reactor technology and hot cell processing facility, which is purpose-built for the simultaneous production of diagnostic and therapeutic medical radioisotopes. These isotopes are essential in diagnosing and treating a wide range of diseases including cancer and heart conditions at a time when their global supply chains are fragile, unreliable, inefficient, and highly concentrated, and at a time when global demand, especially for a new class of cancer-targeting radiotherapeutics, is projected to rapidly increase over the next several decades. The radiotherapy market size is expected to grow from about US$2 billion (CA$2.77 billion) today, to more than US$20 billion (CA$27.7 billion) by 2030.
The project would be Eden's second facility, following the development of its lead reactor project in New Mexico where Eden has completed the U.S. Nuclear Regulatory Commission (NRC) pre-licensing readiness review audits for the principal licensing documents needed for the submittal of its Construction Permit Application (CPA) that is being readied for submission later this year (2025). The foundational technology for Eden's nuclear radioisotope reactor includes IP exclusively licensed from Sandia National Laboratories, funded by the United States Department of Energy (DOE), and accompanied by the R&D team that created it.
Both of Eden's facilities will address the expected future shortfalls and supply constraints for several key medical radioisotopes that are projected to be in much greater demand than the current global supply can serve. Eden's initial focus will be the concurrent production of Molybdenm-99 (Mo-99 - and its daughter product Tc-99m) used in 80% of all diagnostic medical imaging procedures, and Lutetium-177 (Lu-177) which is the primary enabling radioisotope used in the rapidly emerging wave of cancer-targeting radiotherapeutics being developed by most large biopharma and many biotech companies, several of which have been recently approved by the FDA or are in the growing queue of active and planned clinical trials.
Today, Lu-177 is primarily made in the same aging global reactor infrastructure as Mo-99. As potential new Lu-177 based radiotherapies are approved, future new capacity and reliability of supply will be critical especially starting in the 2030 timeframe when Eden's first site is projected to start operating in New Mexico, soon to be followed by the New Brunswick site. Both sites will leverage a unique and proprietary Eden reactor technology advantage - the concurrent and continuous production of multiple clinical radioisotopes.
'CRIP has spent nearly four years laying the groundwork for new nuclear deployments in New Brunswick with our ongoing work to develop an SMR industrial park at the Port of Belledune,' said Andrew Wilder, CEO of CRIP. 'This MOU reflects our belief that Eden's reactor is a strong fit for the nuclear and healthcare ambitions of the province as we launch a new phase of consultation and engagement with Indigenous partners, academic institutions, and regional stakeholders.'
Site selection activities are now underway and will include not only logistical and regulatory criteria but also explore opportunities for educational programming in nuclear engineering and biomedical applications - positioning New Brunswick as a leader in both isotope production and workforce development.
'Eden is excited to build upon the momentum for nuclear infrastructure solutions established by CRIP with the Province of New Brunswick, Canada as the location for the development of our second North American medical radioisotope reactor and hot cell processing facility. It will assure patients, physicians, and biotherapeutic companies throughout North America and beyond with reliable, cost-efficient supply while also contributing to the local economy, 'said Chris Wagner, CEO of Eden. 'Canada has a rich history in being a major contributor and supporter of nuclear medicine and we look forward to being part of their isotope expansion strategy.'
The partners believe Eden's reactor technology is highly compatible with international regulatory cooperation frameworks, including the 2023 Memorandum of Cooperation between the U.S. Nuclear Regulatory Commission (NRC) and the Canadian Nuclear Safety Commission (CNSC) to streamline potential licensing pathways across jurisdictions.
Together, CRIP and Eden aim to ensure priority access to medical isotopes for Canadian healthcare while driving long-term regional economic, educational, and industrial growth. A facility in Atlantic Canada would support Maritime healthcare and serve as a foundational asset for future radiopharmaceutical innovation.
About Eden Radioisotopes
Eden Radioisotopes, LLC is a U.S.-based company that designs and develops proprietary nuclear reactor technology for the safe, cost-effective, and reliable production of medical radioisotopes. Eden's purpose-built LEU reactor is designed specifically to address the global shortage of radioisotopes used in cancer diagnostics and therapy. The company is currently advancing its first reactor in New Mexico and plans to file a Construction Permit Application with the U.S. NRC later this year (2025). Focus Investment Bankers is the exclusive placement agent for Eden's $70 million Series B and related capitalizations.
Corporate Contacts:
For Eden Radioisotopes, LLC
Chris Wagner, Chief Executive Officer
[email protected]
www.edenrad.com
About Cross River Infrastructure Partners
Cross River Infrastructure Partners is a private infrastructure development firm focused on decarbonization, energy transition, and industrial project development in North America. With a history of advancing new nuclear and green industrial development in Atlantic Canada, CRIP has been on the frontline of new SMR planning in the Province of New Brunswick, including its flagship project: the Green Energy Hub at the Port of Belledune.
For Cross River Infrastructure Partners, LLC
Rishi Jain
c: (267) 230-8988
e: [email protected]
www.crossriverllc.com
SOURCE: Eden Radioisotopes, LLC
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Fast Five Quiz: Opioid Use Disorder
Opioid use disorder (OUD) currently impacts approximately 16 million people worldwide. It is considered a significant public health issue, with experts noting a 'burden that is increasing' globally. As research into optimal management of OUD evolves, updates to clinical guidelines emphasize a more individualized approach to pharmacologic treatment, psychosocial support, and special considerations for specific patient populations, such as pregnant individuals. However, OUD remains a complex disease that comes with many serious health and legal concerns for both patients and clinicians. What do you know about OUD? Check your knowledge with this quick quiz. Despite pharmacologic treatment being known to be highly effective for treating OUD, a CDC report states that 30% of patients with OUD who require OUD treatment received only nonpharmacologic treatment. Further, 43% of patients did not perceive a need for OUD treatment at all. In this significant report, males aged 35-49 years were most likely to receive OUD treatment with medications, while females and younger and older adults had lower rates of access to pharmacologic interventions. The CDC concluded that engaging patients needing OUD treatment with pharmacologic interventions is 'essential.' Learn more about essential statistics for OUD. Data from a predictive-model study indicate that service setting was the strongest predictor for premature discontinuation of OUD treatment. The strength of this predictor declined with length of stay, becoming negligent after 365 days. Other system-level factors such as geographic region, primary source of payment for treatment, and referral source were also strong predictors of early discontinuation; individual factors such as age of first use, sex, and race were less predictive. Previous research cited by the study has also stressed the importance of reducing system-level barriers to care, and the updated federal guidance for opioid treatment programs have expanded access in several ways. Learn more about OUD guidance. Precipitated withdrawal can occur when transferring a patient from methadone to buprenorphine due to buprenorphine being only a partial opioid agonist; as such, the traditional method of transfer involves putting the patient in a controlled, moderate withdrawal state before initiating buprenorphine therapy. However, a novel dosing strategy called microinduction, which involves starting buprenorphine at submilligram doses (or 'low-dose induction'), and cross-tapering with methadone can prevent precipitated withdrawal. Additionally, this method is ideal for patients who want to switch from methadone to buprenorphine and those with chronic use of intravenous or intranasal fentanyl. A recent systematic review found that microinduction and traditional transfer methods had similar rates of successful induction of buprenorphine at 95.6%. Learn more about safe withdrawal practices for OUD. Both the CDC and the latest American Society of Addiction Medicine (ASAM) guidelines specifically state that pharmacotherapy for OUD should be offered as early as possible in pregnancy to prevent harms to both the patient and the fetus, noting that pharmacotherapy for OUD has been associated with improved maternal outcomes. ASAM specifically states, 'increasing the dose or split dosing is often required, especially in the third trimester.' Federal guidelines emphasize that pregnant individuals seeking treatment for OUD are considered a priority for enrollment in opioid treatment programs. Once receiving treatment, they do not generally recommended medically supervised withdrawal from pharmacotherapy for pregnant patients as it might harm the fetus and patient; further, ASAM guidelines state that patients who undergo medically supervised withdrawal are at an increased risk for 'return to opioid use.' However, if a patient decides to proceed with medically supervised withdrawal, ASAM guidelines suggest physicians provide education and resources regarding associated risks. The CDC also specifically recommends against abruptly discontinuing opioids during pregnancy, citing data and resources from the American College of Obstetricians and Gynecologists and the Substance Abuse and Mental Health Services Administration. Learn more about OUD. Federal guidelines specify that opioid treatment programs must conduct at least eight random drug tests per year on their patients. These tests must use FDA approved products that test for commonly abused substances that might affect patient safety, recovery, or adherence to OUD treatment. ASAM affirms this requirement, noting that many patients might need more frequent testing and that eight tests per year 'should be viewed as a minimum.' Learn more about drug testing in OUD. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.
Hamilton Spectator
an hour ago
- Hamilton Spectator
NDP leader says Carney needs to keep Parliament in the loop on trade talks
OTTAWA - Interim NDP Leader Don Davies is accusing Prime Minister Mark Carney of not being transparent about negotiations with the U.S. on getting President Donald Trump's tariffs lifted. Davies said Wednesday that Parliament has not been kept in the loop on what Carney and Trump are talking about behind closed doors, or whether Ottawa has involved stakeholders in negotiations with the U.S. 'Previous Liberal governments have made quite a deal out of appointing different stakeholders from society to be present in advising them. Yet we don't know anything about that in these negotiations,' Davies told reporters outside the House of Commons just ahead of question period. 'It's time that Carney government became more transparent with Canadians, let us know who's negotiating, and definitely explain to Canadians why he's pursuing deeper military and economic integration with the United States when he promised Canadians that he would do exactly the opposite.' Carney declared during the recent federal election that Canada's old relationship with the United States, based on deepening economic integration and military cooperation, had come to an end and he vowed to stand up to Trump in the face of steep U.S. tariffs. CBC/Radio-Canada reported earlier Wednesday that the U.S. and Canada are hashing out a 'working document' that outlines details of a potential trade deal and states that Canada will participate in Trump's Golden Dome missile defence project. The prime minister's office is neither confirming nor denying that report. Asked by reporters about talks on the U.S. tariffs, Finance Minister François-Philippe Champagne said the government's 'endgame' is to have all of Trump's tariffs removed, but he referred journalists to Carney and Intergovernmental Affairs Minister Dominic LeBlanc for the most up-to-date information. 'It's a very dynamic situation,' Champagne said. 'We've been engaging with our friends in the United States. You know, we talk to different people in the administration.' But Carney and Foreign Affairs Minister Anita Anand breezed past reporters who shouted questions at them on Wednesday, while LeBlanc was not seen in Parliament. Ontario Premier Doug Ford publicly confirmed the secret, top-level discussions last week, saying that Carney and Trump are in 'deep discussions' on trade and working 'around the clock to get a deal.' 'They're right at the brink,' Ford said in Toronto on June 5. Pete Hoekstra, Trump's ambassador to Canada, said in an armchair talk at the Canadian Club of Ottawa on Wednesday that he thinks there's a 'possibility to have a great deal.' He said that 'all indications' are that the two countries could reach a 'very positive agreement,' but couched that 'there's also the possibility you could end up with something like no deal or whatever.' 'Until a deal is announced, you really won't know what's it in it,' Hoekstra said. Trump has insisted that Canada could join his unbuilt Golden Dome continental missile defence program at a cost of $61 billion. Carney confirmed last month that he is in talks with Trump about the project. 'It's something that we are looking at and something that has been discussed at a high level,' Carney said at a press conference in Ottawa on May 21. This report by The Canadian Press was first published June 11, 2025.
Hamilton Spectator
an hour ago
- Hamilton Spectator
Trigon finalizes $750M investment in North Coast LPG facility
Trigon Pacific Terminals' board passed its final investment decision today (June 11) on a $750 million liquefied petroleum gas (LPG) export facility in Prince Rupert despite a current exclusivity deal between the Prince Rupert Port Authority and an Altagas/Royal Vopak partnership. The facility will be able to export up to 2.5 million tonnes of primarily Alberta-produced propane and butane annually, positioning it as a major LPG export hub in Canada. Pending all required legal and regulatory approvals, the company could begin exports by late 2029. 'We've come to the table with investment dollars and now we need the federal government to expedite this shovel-ready project that is clearly in the national interest,' said Trigon CEO Rob Booker. Booker pointed out that the project aligns with Canada's economic goals of trade diversification and expanding exports of critical minerals and clean energy to global markets beyond the U.S., particularly in Asia. While Alberta supplies the product, Trigon offers reliable coastal access needed to move it to international markets quickly, he said. 'We want to keep this project moving along because we have some momentum now,' said Craig Olley, Trigon's president. He noted that Asian buyers currently lack open access to LPG, which Trigon aims to offer by entering the market. 'We have a sort of responsibility to provide open market, fair access to the consumers in Japan, and currently, today, they don't have that.' The president added that AltaGas and Royal Vopak cuurently hold exclusive rights to export this type of energy out of Prince Rupert, effectively giving them a monopoly on the West Coast. 'It's always good to have some healthy competition,' said Olley. He recently returned from Japan as part of the business delegation accompanying Premier David Eby on his trade tour. He highlighted the strong LPG demand in Japan and South Korea, noting that Malaysia has also begun to show interest. 'At least a dozen different entities were supportive and pleased to see Trigon stepping up to facilitate LPG movement into Asia. They understand that Prime Minister Carney is supportive of these cleaner, lower-emission type fuels for energy use in Asia,' said Olley. In February, amid the Canada-U.S. tariff dispute, Booker wrote to the Prime Minister urging the federal government to direct the Prince Rupert Port Authority (PRPA) to revoke the exclusive LPG export access granted to AltaGas and Royal Vopak. The port authority, which had already partnered with the two companies on a $1.35 billion export facility in the city maintained its position against allowing Trigon to expand LPG operations on Ridley Island. Olley noted that Trigon already has key infrastructure in place, including LPG loading arms, existing rail connections, and marine berth access, which removes the need for new construction. He said AltaGas and Royal Vopak currently use Trigon's loading arms for their LPG exports. He confirmed that the existing setup can also handle Trigon's own exports in the future. Trigon's June 11 news release highlighted support from Chief Councillor Garry Reece of the Lax Kw'alaams Band, Chief Robert Nelson of the Metlakatla First Nation, and the Government of Alberta on this project. 'We have some of the largest reserves of natural gas and natural gas liquids in the world and are working hard to meet the growing demand of our partners in Japan, Korea and Asia. This new Indigenous-backed facility will play a major role in the long-term success of these partnerships and in promoting Indigenous economic reconciliation,' stated Brian Jean, Alberta Minister of Energy and Minerals. As of 2024, Trigon Pacific Terminals is the largest terminal by volume at the Port of Prince Rupert, having handled 9.1 million metric tonnes of dry and liquid bulk products. The multi-commodity bulk terminal ships various materials, including steelmaking and thermal coal, petroleum coke, iron ore pellets, and liquid propane gas (LPG). According to the Canadian government, Canada produced 46.7 million tonnes of coal in 2022. Of that, 59 per cent was metallurgical coal used in steelmaking, while 41 per cent was thermal coal used for electricity generation. The government noted that coal-fired power remains the largest global source of greenhouse gas emissions, contributing to climate change and posing health risks. When asked whether Trigon would scale back its thermal coal exports once its zero-emission ammonia/hydrogen and lower-emission LPG facilities become operational, the company said it would remain committed to continuing current coal exports. 'We understand the importance of these resources to various industries and economies; the world will always need steel, and many countries still rely on thermal coal for energy. We are dedicated to maintaining our operations to support their needs,' said Olley. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
